JP2022527630A5 - - Google Patents

Info

Publication number
JP2022527630A5
JP2022527630A5 JP2021560228A JP2021560228A JP2022527630A5 JP 2022527630 A5 JP2022527630 A5 JP 2022527630A5 JP 2021560228 A JP2021560228 A JP 2021560228A JP 2021560228 A JP2021560228 A JP 2021560228A JP 2022527630 A5 JP2022527630 A5 JP 2022527630A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
composition according
sucralose
citric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021560228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527630A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/026696 external-priority patent/WO2020206336A1/en
Publication of JP2022527630A publication Critical patent/JP2022527630A/ja
Publication of JP2022527630A5 publication Critical patent/JP2022527630A5/ja
Pending legal-status Critical Current

Links

JP2021560228A 2019-04-05 2020-04-03 鎌状赤血球症を治療するためのpde9阻害剤 Pending JP2022527630A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962829784P 2019-04-05 2019-04-05
US62/829,784 2019-04-05
PCT/US2020/026696 WO2020206336A1 (en) 2019-04-05 2020-04-03 Pde9 inhibitors for treating sickle cell disease

Publications (2)

Publication Number Publication Date
JP2022527630A JP2022527630A (ja) 2022-06-02
JP2022527630A5 true JP2022527630A5 (cg-RX-API-DMAC7.html) 2023-04-10

Family

ID=72666968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560228A Pending JP2022527630A (ja) 2019-04-05 2020-04-03 鎌状赤血球症を治療するためのpde9阻害剤

Country Status (9)

Country Link
US (1) US20220023302A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946348A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022527630A (cg-RX-API-DMAC7.html)
CN (1) CN114302724A (cg-RX-API-DMAC7.html)
BR (1) BR112021019876A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136128A1 (cg-RX-API-DMAC7.html)
IL (1) IL286976A (cg-RX-API-DMAC7.html)
WO (1) WO2020206336A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107544B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1928237A4 (en) * 2005-09-02 2011-03-09 Abbott Lab NEW HETEROCYCLES BASED ON IMIDAZO
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
MX381326B (es) * 2011-10-10 2025-03-12 H Lundbeck As Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
CA2990521C (en) * 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
UA125025C2 (uk) * 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Способи лікування дитячих ракових захворювань
IL295973A (en) * 2016-07-06 2022-10-01 H Lundbeck As pde9 inhibitors for the treatment of peripheral diseases
HUE065158T2 (hu) * 2017-05-26 2024-05-28 Cardurion Pharmaceuticals Inc PDE9 gátlószereinek elõállítására és alkalmazására szolgáló eljárások
CN114072151A (zh) * 2019-05-07 2022-02-18 伊马拉公司 用于治疗地中海贫血的pde9抑制剂

Similar Documents

Publication Publication Date Title
JP2025142338A5 (cg-RX-API-DMAC7.html)
CN101171005A (zh) Pde4抑制剂罗氟司特与四氢生物蝶呤衍生物的组合
ES2259098T3 (es) Composiciones que comprenden ipatropio y xilometazolina para el tratamiento del resfriado comun.
KR100841893B1 (ko) 프레가발린 조성물
US20080132517A1 (en) Method of enhancing absorptions of transmucosal administration formulations
CA2782734C (en) Nicotine containing formulation
CN111683683A (zh) Pde v抑制剂的液体口服制剂
CN102470099A (zh) 儿童用奥洛他定鼻腔喷雾方案
ES2791775A2 (es) Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades
JP2024510287A (ja) L-セリン又はその薬学的に許容される塩の液体製剤及びそれを調製するための方法
JPH07505645A (ja) 医薬組成物
ES2239802T3 (es) Composiciones farmaceuticas.
JP5314014B2 (ja) テルビブジンを含む医薬内用液
JP2022536669A5 (cg-RX-API-DMAC7.html)
TWI327913B (en) Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
JP2007269786A (ja) パンテチン含有経口液剤
CN105213402A (zh) 一种畜禽复方恩诺沙星美洛昔康可溶性粉
PT1482938E (pt) Composição farmacêutica de um inibidor da pde4 ou de um inibidor da pde3/4 e um antagonista dos receptores histamínicos
WO2011093831A2 (en) Effervescent formulations comprising cefprozil as active agent
CN121285367A (zh) 包含布洛芬的药物组合物
ES2629103T3 (es) Formulación en polvo de valganciclovir
WO2018053423A1 (en) Pharmaceutical composition of ibuprofen sodium for oral administration
JP2003512421A5 (cg-RX-API-DMAC7.html)
JP2006528160A (ja) 抗血栓性化合物の口腔分散性医薬組成物
JPH11139970A (ja) 経口液剤